2023 Form 5500 filing — Aclaris Therapeutics Inc 401(K) Plan

Plain-English filing summary

According to public Form 5500 filings published through the U.S. Department of Labor (DOL) Employee Benefits Security Administration (EBSA) via the EFAST2 system, this is the 2023 Form 5500 filing (EFAST2 acknowledgement 20241014091723NAL0025804065001) for Aclaris Therapeutics Inc 401(K) Plan, reported by Aclaris Therapeutics Inc under EIN 46-0571712 and plan number 001. It reports 154 participants. Attached schedules in the loaded dataset include Schedule H (large plan financials), Schedule C (service provider compensation).

EFAST2 acknowledgement
20241014091723NAL0025804065001
Filing year
2023
Form type
2
Plan sponsor
Aclaris Therapeutics Inc
EIN
46-0571712
Plan number
001
Location
Wayne, PA
Participants
154
Schedules available
Schedule H, Schedule C
Received date
not reported in the loaded dataset

Reported financial snapshot (2023)

Total assets (EOY)
$12,430,834
Total liabilities (EOY)
$0
Net assets (EOY)
$12,430,834
Employer contributions
$707,520
Participant contributions
$1,712,221
Total income / additions
$4,675,015
Benefits paid
$1,553,142
Administrative expenses
$32,815
Total expenses
$1,590,228
Net increase / (decrease)
$3,084,787
Schedule source
Schedule H

Reported service provider compensation (Schedule C)

Compensation reported on the 2023 filing
ProviderServiceDirect comp.Indirect comp.
T. Rowe Price Rps, Inc.NONE$32,815$0
Pimco FundsNONE$0$0
Alliance Global FundsNONE$0$0
Prudential JennisonNONE$0$0
American FundsNONE$0$0
Tiaa-Cref FundsNONE$0$0
FidelityNONE$0$0
Principal FundsNONE$0$0
Jp Morgan FundsNONE$0$0
Janus FundsNONE$0$0

Related Form 5500 pages